5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
BUY | BUY | BUY | BUY | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 1.95▲ | 1.94▲ | 1.95▲ | 1.87▲ | 1.64▲ |
MA10 | 1.96▲ | 1.93▲ | 1.91▲ | 1.76▲ | 4.13▼ |
MA20 | 1.92▲ | 1.87▲ | 1.86▲ | 1.59▲ | 7.67▼ |
MA50 | 1.85▲ | 1.82▲ | 1.77▲ | 4.32▼ | 15.89▼ |
MA100 | 1.83▲ | 1.69▲ | 1.60▲ | 8.10▼ | N/A |
MA200 | 1.69▲ | 1.59▲ | 3.38▼ | 9.81▼ | N/A |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.000▼ | 0.009▲ | 0.011▲ | 0.272▲ | 6.418▲ |
RSI | 59.518▲ | 62.804▲ | 63.302▲ | 38.985▼ | 19.685▼ |
STOCH | 48.179 | 62.848 | 75.581 | 65.441 | 4.387▼ |
WILL %R | -17.647▲ | -11.111▲ | -10.714▲ | -10.588▲ | -91.481▼ |
CCI | 110.402▲ | 131.274▲ | 143.281▲ | 130.671▲ | -101.552▼ |
Wednesday, April 16, 2025 12:35 AM
For more information about the 2025 ATS International Conference, please visit the conference website, here. About GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally ...
|
Tuesday, April 15, 2025 10:35 PM
GRI Bio is a clinical-stage biopharmaceutical ... the inability to maintain the listing of the Company’s common stock on The Nasdaq Capital Market and to comply with applicable listing ...
|
Tuesday, April 15, 2025 10:35 PM
LA JOLLA, CA, April 16, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
02/05/25 | 2.05 | 2.05 | 1.88 | 2.02 | 59,388 |
01/05/25 | 1.80 | 2.053 | 1.80 | 1.95 | 186,403 |
30/04/25 | 1.80 | 1.875 | 1.73 | 1.82 | 126,209 |
29/04/25 | 1.72 | 1.84 | 1.66 | 1.77 | 137,537 |
28/04/25 | 1.82 | 1.93 | 1.69 | 1.78 | 167,646 |
25/04/25 | 1.70 | 1.87 | 1.60 | 1.82 | 240,889 |
24/04/25 | 1.78 | 1.88 | 1.67 | 1.67 | 373,400 |
23/04/25 | 1.51 | 2.11 | 1.51 | 1.84 | 1,261,520 |
22/04/25 | 1.49 | 1.68 | 1.43 | 1.45 | 183,499 |
21/04/25 | 1.45 | 1.51 | 1.41 | 1.46 | 98,655 |
|
|
||||
|
|
||||
|
|